Aspen Neuroscience

Name

Aspen Neuroscience

Legal name

Aspen Neuroscience, Inc.

Website

https://aspenneuroscience.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Autologous cell therapy
• IPSC-derived therapies
• Regenerative medicine
• Parkinson's disease treatment
• Neuron replacement therapy

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Autologous Cell Therapy Commercialization: Aspen Neuroscience is a pre-revenue clinical-stage company developing personalized autologous iPSC-derived cell therapies. The primary revenue stream will come from commercialization of ANPD001 (sasineprocel) for Parkinson's disease treatment upon FDA approval. The company is preparing for commercial launch with the appointment of a Chief Commercial Officer and expansion of manufacturing capabilities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Aspen Neuroscience develops personalized autologous cell replacement therapies derived from a patient's own induced pluripotent stem cells (iPSCs), beginning with ANPD001 (Sasineprocel) for moderate-to-advanced Parkinson's disease. The therapy uses patient skin cells converted to iPSCs, differentiated into dopaminergic neuron precursors, and administered via image-guided intracranial injection to the putamen without immunosuppression. Manufacturing is conducted at a 22,000 sq. ft. GMP facility in San Diego with proprietary machine-learning-based genomic quality controls at every stage.

Product overview

Aspen Neuroscience is a clinical-stage regenerative medicine biotechnology company developing personalized autologous iPSC-derived cell replacement therapies. The company's lead product is ANPD001, now officially named Sasineprocel, an autologous dopaminergic neuronal precursor cell therapy for Parkinson's disease. The therapy is manufactured using a proprietary platform that converts patient skin cells to iPSCs, then differentiates them into dopamine-producing neurons, administered via image-guided intracranial injection. The company operates GMP manufacturing facilities in San Diego and is conducting the ASPIRO Phase 1/2a clinical trial with plans for Phase 3 advancement.

Differentiator

Problem solved

Functional benefit

Brands

• Sasineprocel (ANPD001): Autologous iPSC-derived dopaminergic neuron precursor cell (DANPC) therapy for Parkinson's disease; replaces lost dopamine-producing neurons via image-guided intracranial injection without requiring immunosuppressive drugs

Products and services

• ANPD001 (Sasineprocel) Autologous dopaminergic neuronal precursor cell (DANPC) therapy derived from the patient's own iPSCs for the treatment of moderate-to-advanced Parkinson's disease, administered via image-guided intracranial injection to the putamen without requiring immunosuppression. Most advanced autologous investigational cell therapy for Parkinson's in the United States, with FDA Fast Track designation and Phase 1/2a ASPIRO trial underway.

Quantifiable outcome

• Mean Good ON time increased by +2.1 to +2.4 hours at 12 months post-treatment
• +5 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• MytoscoreTechnology or Integration · 8 January 2025Manufacturing collaboration to automate production of dopaminergic neuronal precursor cells (DANPCs) for ANPD001. Mytos provides automated cell manufacturing platform to help Aspen scale production and treat greater numbers of patients.
• Cell X TechnologiescoreTechnology or Integration · 8 October 2024Collaboration and license agreement to advance automation of the iPSC stage of Aspen's autologous manufacturing platform. Cell X leads development of its Celligent platform including Cx Suite and Colonyze, while Aspen leverages its bioinformatics-based platform and leads all discovery, preclinical, development, and commercialization activities.
• ClearPoint (MRI-guided Navigation System)coreTechnology or Integration · 20 June 2024ClearPoint Navigation System used for MRI-guided precision implantation of ANPD001 in the ASPIRO clinical trial, enabling sub-millimeter accuracy in cell transplantation.
• Rune LabsminorStrategic or Co-development Partner · 24 August 2023Partnership to incorporate active digital health monitoring in the Trial-Ready Screening Cohort Study using Rune Labs' software and data analytics for precision neurology.
• Emerald InnovationsminorStrategic or Co-development Partner · 24 August 2023Partnership to incorporate passive digital health monitoring using Emerald Innovations' invisible off-body sensors for measuring health analytics in Parkinson's disease patients.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Century Therapeutics: Century Therapeutics is an emerging cell therapy company developing iPSC-derived allogeneic immune cell therapies for cancer. While focused on oncology, it represents a comparable peer in iPSC-derived engineered cell therapy manufacturing and platform development.
• Fate Therapeutics: Fate Therapeutics is a clinical-stage cell therapy company developing iPSC-derived off-the-shelf NK and T-cell therapies. Comparable as a peer for iPSC-based cell therapy platforms, GMP manufacturing of engineered cell products, and clinical/commercial readiness for novel modalities.
• Sana Biotechnology: Sana Biotechnology is developing engineered cell therapies, including iPSC-derived platforms, for cancer and other diseases. Comparable as a peer advancing iPSC-based platforms toward clinical and commercial scale with deep manufacturing and QC expertise.
• Lineage Cell Therapeutics: Lineage Cell Therapeutics (formerly BioTime, which acquired Asterias) develops allogeneic cell transplant therapies including OPC1 for spinal cord injury and programs for CNS indications. Comparable as a peer in CNS cell therapy clinical translation with shared scientific lineage to historical stem cell programs.
• Sumitomo Pharma: Sumitomo Pharma (with Kyoto University/CiRA researchers) is developing an iPSC-derived dopaminergic neuron cell therapy for Parkinson's disease in Japan. It represents an emerging global competitor in autologous/allogeneic PD cell therapy with strong academic backing and clinical activity in Asia.
• Nkarta: Nkarta is a clinical-stage cell therapy company developing allogeneic and autologous NK cell therapies for cancer. Comparable as an emerging peer in cell therapy manufacturing, GMP operations, and clinical pipeline development.

Others

• Lonza Group: Lonza is a leading contract manufacturer of cell and gene therapies with cell therapy-specific manufacturing services. Aspen's CTO Kim Raineri previously led Lonza cell therapy operations. Relevant as an enabler/infrastructure peer for scalable autologous and allogeneic cell therapy manufacturing rather than a direct product competitor.

Broad incumbents

• Bayer AG (Cell & Gene Therapy): Bayer acquired BlueRock Therapeutics in 2019 to build a cell therapy franchise including Parkinson's disease, and operates AskBio and other gene/cell therapy assets. As the parent of Aspen's closest direct peer, it competes broadly in the same therapeutic and modality space with far greater resources.
• Vertex Pharmaceuticals (Cell Therapy): Vertex has built a cell therapy program including VX-880 for type 1 diabetes (originally developed by Semma Therapeutics using stem cell-derived islet cells). While targeting a different indication, Vertex demonstrates the commercial viability of stem cell-derived autologous/allogeneic cell therapies at scale.

Direct peers

• BlueRock Therapeutics: BlueRock Therapeutics (acquired by Bayer for ~$1B in 2019) is the most direct competitor, developing iPSC-derived dopaminergic neuron cell therapies for Parkinson's disease. Both companies target the same indication with stem cell-derived neuron replacement, but BlueRock pursues an off-the-shelf allogeneic approach versus Aspen's autologous model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/AspenNeuro
• LinkedInlinkedin.com/company/aspen-neuroscience
• Facebookfacebook.com/AspenNeuroscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds6 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspen Neuroscience